Phase 2 Clinical Trial of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary Fibrosis

NCT07679893 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

153

Enrollment

INDUSTRY

Sponsor class

Conditions

Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis (IPF)

Interventions

DRUG: Nintedanib Dry Powder Inhalation
DRUG: Placebo

Sponsor

Mannkind Corporation